Phase 1 Graft-Versus-Host Disease Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Graft-Versus-Host Disease
Northwell Health74 enrolled1 locationNCT05289167
Recruiting
Phase 1
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Acute Myeloid LeukemiaMyelodysplastic SyndromeGraft-Versus-Host Disease
City of Hope Medical Center15 enrolled1 locationNCT06996119
Recruiting
Phase 1
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Graft vs Host DiseaseGraft-Versus-Host Disease
Washington University School of Medicine41 enrolled1 locationNCT06008808
Recruiting
Phase 1
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Graft-Versus-Host Disease
Henry Ford Health System18 enrolled1 locationNCT04886726
Recruiting
Phase 1
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Graft-Versus-Host DiseaseXerostomiaSjogren's Disease
University of Wisconsin, Madison36 enrolled1 locationNCT06392711
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers
Acute graft-versus-host disease (aGvHD)
NapaJen Pharma Inc.104 enrolled1 locationACTRN12618001428257
Not Yet Recruiting
Phase 1
Pharmacokinetics and Safety of Solid Oral Posaconazole(SCH 56592) in Subjects at High Risk for Invasive Fungal Infections
High Risk for Invasive Fungal Infection due to:
- Hematopoietic stem cell transplant (HSCT) recipients undergoing treatment for graft-versus-host disease (GVHD)High Risk for Invasive Fungal Infection due to:
- Expected neutropenia (low white blood cell count) due to chemotherapy for Acute Myelogenous Leukaemia (AML) or Myelodysplastic Syndrome (MDS)
Schering-Plough Pty limited160 enrolled1 locationACTRN12611000364976